MiR-106b promotes cell proliferation via targeting RB in laryngeal carcinoma

Journal of Experimental and Clinical Cancer Research

Volumn 30, Issue 1, 2011, Pages

  Cai, Kemin ^a   Wang, Yu ^a   Bao, Xueli ^a  

^a TAIZHOU PEOPLE S HOSPITAL   (China)

Author keywords

cell proliferation; laryngeal carcinoma; miR 106b; RB

Indexed keywords

COMPLEMENTARY DNA; MICRORNA; MICRORNA 106B; RETINOBLASTOMA PROTEIN; UNCLASSIFIED DRUG; ANTISENSE OLIGONUCLEOTIDE; MIRN106 MICRORNA, HUMAN;

3' UNTRANSLATED REGION; ARTICLE; CANCER INHIBITION; CARCINOMA CELL; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; LARYNX CARCINOMA; PRIORITY JOURNAL; PROTEIN TARGETING; WESTERN BLOTTING; BIOSYNTHESIS; CELL GROWTH; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; LARYNX TUMOR; METABOLISM; TUMOR CELL LINE;

3' UNTRANSLATED REGIONS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; DNA, COMPLEMENTARY; G0 PHASE; G1 PHASE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LARYNGEAL NEOPLASMS; MICRORNAS; OLIGONUCLEOTIDES, ANTISENSE; RETINOBLASTOMA PROTEIN; TRANSFECTION;

EID: 79961124478     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-30-73     Document Type: Article

References (20)

1. Current opinion in diagnosis and treatment of laryngeal carcinoma. Marioni G, Marchese-Ragona R, Cartei G, Marchese F, Staffieri A, Cancer Treat Rev 2006 32 504 515 10.1016/j.ctrv.2006.07.002 16920269 (Pubitemid 44488046)
2. Survival after laryngectomy: a review of 133 patients with laryngeal carcinoma. Papadas TA, Alexopoulos EC, Mallis A, Jelastopulu E, Mastronikolis NS, Goumas P, Eur Arch Otorhinolaryngol 2010 267 1095 1101 10.1007/s00405-009- 1156-8 19921233
3. hsa-mir-181a and hsa-mir-181b function as tumor suppressors in human glioma cells. Shi L, Cheng Z, Zhang J, Li R, Zhao P, Fu Z, You Y, Brain Res 2008 1236 185 193 18710654
4. MicroRNA roles in beta-catenin pathway. Huang K, Zhang JX, Han L, You YP, Jiang T, Pu PY, Kang CS, Mol Cancer 2010 9 252 10.1186/1476-4598-9-252 20858269
5. Let-7a microRNA functions as a potential tumor suppressor in human laryngeal cancer. Long XB, Sun GB, Hu S, Liang GT, Wang N, Zhang XH, Cao PP, Zhen HT, Cui YH, Liu Z, Oncol Rep 2009 22 1189 1195 19787239
6. Comprehensive MicroRNA profiling for head and neck squamous cell carcinomas. Hui AB, Lenarduzzi M, Krushel T, Waldron L, Pintilie M, Shi W, Perez-Ordonez B, Jurisica I, O'Sullivan B, Waldron J, et al. Clin Cancer Res 2010 16 1129 1139 10.1158/1078-0432.CCR-09-2166 20145181
7. Role of the miR-106b-25 microRNA cluster in hepatocellular carcinoma. Li Y, Tan W, Neo TW, Aung MO, Wasser S, Lim SG, Tan TM, Cancer Sci 2009 100 1234 1242 10.1111/j.1349-7006.2009.01164.x 19486339
8. Down-regulation of microRNA 106b is involved in p21-mediated cell cycle arrest in response to radiation in prostate cancer cells. Li B, Shi XB, Nori D, Chao CK, Chen AM, Valicenti R, White Rde V, Prostate 2011 71 567 574 10.1002/pros.21272 20878953
9. Circulating microRNAs in plasma of patients with gastric cancers. Tsujiura M, Ichikawa D, Komatsu S, Shiozaki A, Takeshita H, Kosuga T, Konishi H, Morimura R, Deguchi K, Fujiwara H, et al. Br J Cancer 2010 102 1174 1179 10.1038/sj.bjc.6605608 20234369
10. Expression of miRNA-106b in conventional renal cell carcinoma is a potential marker for prediction of early metastasis after nephrectomy. Slaby O, Jancovicova J, Lakomy R, Svoboda M, Poprach A, Fabian P, Kren L, Michalek J, Vyzula R, J Exp Clin Cancer Res 2010 29 90 10.1186/1756-9966-29-90 20609231
11. MicroRNAs in the miR-106b family regulate p21/CDKN1A and promote cell cycle progression. Ivanovska I, Ball AS, Diaz RL, Magnus JF, Kibukawa M, Schelter JM, Kobayashi SV, Lim L, Burchard J, Jackson AL, et al. Mol Cell Biol 2008 28 2167 2174 10.1128/MCB.01977-07 18212054 (Pubitemid 351429964)
12. miR-106b aberrantly expressed in a double transgenic mouse model for Alzheimer's disease targets TGF-beta type II receptor. Wang H, Liu J, Zong Y, Xu Y, Deng W, Zhu H, Liu Y, Ma C, Huang L, Zhang L, Qin C, Brain Res 2010 1357 166 174 20709030
13. Cell-context specific role of the E2F/Rb pathway in development and disease. Swiss VA, Casaccia P, Glia 2010 58 377 390 19795505
14. The rb pathway and cancer therapeutics. Du W, Searle JS, Curr Drug Targets 2009 10 581 589 19601762
15. Targeting the RB-pathway in cancer therapy. Knudsen ES, Wang JY, Clin Cancer Res 2010 16 1094 1099 10.1158/1078-0432.CCR-09-0787 20145169
16. RB pathway and therapeutic sensitivity: New insights in breast cancer and Tamoxifen therapy. Witkiewicz AK, Knudsen ES, Cell Cycle 2011 10
17. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008 455 1061 1068 10.1038/nature07385 18772890
18. Loss of heterozygosity for Rb locus and pRb immunostaining in laryngeal cancer: a clinicopathologic, molecular and immunohistochemical study. Pietruszewska W, Klatka J, Borzecki A, Rieske P, Folia Histochem Cytobiol 2008 46 479 485 10.2478/v10042-008-0076-6 19141402
19. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Fry DW, Harvey PJ, Keller PR, Elliott WL, Meade M, Trachet E, Albassam M, Zheng X, Leopold WR, Pryer NK, Toogood PL, Mol Cancer Ther 2004 3 1427 1438 15542782
20. Treatment of growing teratoma syndrome. Vaughn DJ, Flaherty K, Lal P, Gallagher M, O'Dwyer P, Wilner K, Chen I, Schwartz G, N Engl J Med 2009 360 423 424 10.1056/NEJMc0808558 19164198